FDA shakes up weight loss market as Mounjaro shortage ends
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
3 No-Brainer Growth Stocks to Buy in October
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
How a medtech market opportunity is shaping up for wearable neurotech
When you think of brain stimulating medtech, startups building wearables as therapeutics probably aren't the first thing that ...
Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics
Viking Therapeutics (NASDAQ: VKTX) and Summit Therapeutics (NASDAQ: SMMT) are both up-and-coming biotechs with no sales ...
The Jerusalem Post Blogs5h
Best Ozempic Alternatives to Burn Fat Naturally: OTC Compounded Semaglutide Options to Try
Semaglutide, which is known for its effectiveness in weight control, particularly for individuals suffering from obesity ...
You can now dress up as a ‘sexy Ozempic shot’ this Halloween
An online store has jumped on the Ozempic craze by releasing a “sexy” semaglutide injection costume just in time for ...
MarketBeat on MSN16h
Why Eli Lilly Stock Is Soaring-and How It Plans to Stay on Top
In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company ...
Morningstar14h
Obesity Drug Market: The Next Wave of GLP-1 Competition
New drugs from public and private companies are expected to saturate the obesity drug market. Novo Nordisk and Eli Lilly are currently dominating the weight loss drug market, but biopharmaceutical ...
Deutsche Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU)
In a report released on October 10, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novo Nordisk (0QIU – Research ...